ClinicalTrials.gg
CompletedNCT05831319BIO-OSCAR SOCUpdated Nov 1, 2024

Evaluation of Standard of Care Practices, Procedural Outcomes and In-hospital Complications of Peripheral Endovascular Procedures

An observational study in Peripheral Arterial Disease, sponsored by Biotronik AG. Completed at 17 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Biotronik AG (formerly part of Biotronik SE & Co. KG) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
380
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG — 1 open to participants now, 2 under way, none of them phase 3. Peripheral Arterial Disease · Biotronik SE & Co. KG.

Started
2023
the only one that year
Observational
7 of 15
1 open now
Registered
13th of 15
by date

Among the 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG, this one is the only one that started in 2023, is one of 7 observational ones, and was the 13th registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

1 of the 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG, or all of them as a file.
02

Study summary

Significant advances in dedicated materials and techniques along with increased operator experience led to a significant increment in procedural success rate of peripheral endovascular interventions, exceeding 90% in expert hands with reported low procedural complication rates. However, there are still lack of data on procedural outcomes, in-hospital complications, and resource utilization on treatment of (complex) lesions in the femoral, popliteal and infrapopliteal artery in the real-world condition in Europe.

Read the detailed description

The study will enroll consecutive eligible subjects who have peripheral artery disease (PAD) requiring endovascular treatment of de-novo and restenotic atherosclerotic lesions in femoral, popliteal and infrapopliteal arteries.

The purpose of this prospective, multicenter, observational European Study is to evaluate the standard of care practices, procedural outcomes, and in-hospital complications of endovascular peripheral interventions for treatment of lesions in the femoral, popliteal and infrapopliteal arteries.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects who have PAD with target lesion(s) located in the femoral, popliteal and/or infrapopliteal artery are eligible for the study. Up to 380 subjects will be enrolled in approximately 12 investigational sites in Europe.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject ≥18 years old
  2. Subject has provided written
  3. Subject has Rutherford classification 2 to 6
  4. Reference vessel diameter ≥2 and ≤7 mm
  5. Target lesion(s) has stenosis >70% by visual assessment
  6. Multiple consecutive single lesions with a healthy segment(s) of ≤ 3cm in-between the lesions will be considered one lesion.

    For Above the knee (ATK) group

  7. Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau)
  8. At least 1 below-knee artery patent to the ankle
  9. Successful treatment of inflow iliac stenosis to the target lesion. Inflow lesion stenosis can be treated during the same procedure as per local standard of care.

    For Below the knee (BTK) group:

  10. Target lesions involve arteries below the tibial plateau
  11. Successful treatment of inflow vessel (from ipsilateral iliac to the target lesion) resulting in ≤30% residual stenosis with no evidence of embolization or significant complications.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a single target lesion that involves both ATK and BTK segment.
  2. Subject not suitable for receiving endovascular procedures of lower limb arteries
  3. Prior planned major amputation in the target limb (above the ankle)
  4. Subject with previous bypass surgery of target vessel.
  5. History of any open surgical procedure within the past 30 days.
  6. Planned vascular surgery procedure within the next 30 days after the ATK and/or BTK procedure on the target limb. Note: The inflow vessels can be treated on the day of the procedure
  7. Subject under dialysis
  8. Subject currently enrolled in another device, biologic, or drug trial in which the primary endpoint has not yet been reached
  9. Subject lacking capacity to provide
  10. Subject under judicial protection, tutorship, or curatorship (for France only)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
380 participants (actual)
Patient registry
No

Groups and cohorts

  • Above the knee (ATK) group

    Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau)

  • Below the knee (BTK) group

    Target lesions involve arteries below the tibial plateau

06

What researchers measure

Primary outcomes

  1. Procedural success rate

    Combination of technical success and absence of procedural complications

    Time frame: Index Procedure

Secondary outcomes

  1. Procedure technical success rate

    successful crossing and achievement of a final residual diameter stenosis of ≤30% of the treated target lesion on the procedural completion angiography

    Time frame: Index Procedure

  2. Rate of target lesion bailout stenting

    Stented target lesion

    Time frame: Index Procedure

  3. Stented length

    Stented length

    Time frame: Index Procedure

  4. Rate of PTA balloon related flow-limiting dissections

    PTA balloon related flow-limiting dissections

    Time frame: Index Procedure

  5. Rate of distal embolization

    Distal embolization

    Time frame: Index Procedure

  6. Rate of target vessel rupture

    Target vessel rupture

    Time frame: Index Procedure

  7. Rate of target vessel perforation

    Target vessel perforation

    Time frame: Index Procedure

  8. Rate of acute occlusion

    Acute occlusion

    Time frame: Index Procedure

  9. Primary crossing success rate

    Successfully placement of a guidewire into the distal true lumen with the primary crossing strategy

    Time frame: Index Procedure

  10. Rate of Serious Adverse Device Effects

    Serious Adverse Device Effects

    Time frame: Index Procedure

  11. Non-labor resource use

    Devices use

    Time frame: Index procedure until discharge

07

Study locations

17 sites
  • LKH Univ.-Klinikum Graz, Ambulanz für Angiologie
    Graz, Austria
  • OLV Ziekenhuis Aalst
    Aalst, Belgium
  • A.Z. Sint-Blasius
    Dendermonde, Belgium
  • Ziekenhuis Oost Limburg
    Genk, 3600, Belgium
  • University Hospital Ghent
    Ghent, 9000, Belgium
  • vzw AZ Groeninge
    Kortrijk, 8500, Belgium
  • Hopital Paris Saint Joseph
    Paris, France
  • Karolinen-Hospital, Klinikum Arnsberg
    Arnsberg, Germany
  • Sank Gertrauden-Krankenhaus
    Berlin, Germany
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Semmelweis University Hospital
    Budapest, Hungary
  • Policlinico Abano Terme
    Abano Terme, 35031, Italy
  • Azienda Usl Toscana sud est
    Arezzo, 52100, Italy
  • ospedaliero-universitaria Senese
    Sienna, 53100, Italy
  • Hospital General de Guadalajara
    Guadalajara, Spain
  • Ospedale Regionale di Lugano
    Lugano, 6962, Switzerland
  • KS Winterthur
    Winterthur, Switzerland
08

References and documents

Individual participant data

Plan to share: Undecided — The individual participant data (IPD) is not yet drafted. No decision is taken to share it yet.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jun 2024, 12 months.

Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 12 months is below that.

Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2023
First posted
Apr 26, 2023
StartActual
May 29, 2023
Primary completionActual
Jun 1, 2024
CompletionActual
Oct 30, 2024
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05831319
Lead sponsor
Biotronik AG
Responsible party
Sponsor
First posted
Apr 26, 2023
Start date
May 29, 2023
Primary completion
Jun 1, 2024
Completion
Oct 30, 2024
Last update
Nov 1, 2024

Study contacts

Deloose Koen, Dr
study chair · AZ Saint Blasius, Dendermonde, Belgium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion